Overexpression of basic fibroblast growth factoris a potential indicator of worse prognosis for patients with operable NSCLC and SCLC
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Basic fibroblast growth factor (bFGF) is known to stimulate angiogenesis, and overexpression is a potential indicator of worse prognosis for patients with operable non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Meta-analysis of 22 studies (n = 2154),and endpoints were pooled hazard ratios (HR) for overall survival (OS).
Combined HR suggests that bFGF overexpression had an adverse impact on survival of patients with lung cancer(HR = 1.202,95%CI, 1.022-1.382).
Subgroup analysis showed that the combined HR evaluating bFGF expression on OS in operable NSCLC was 1.553 (95%CI, 1.120-1.986) and the combined HR in SCLC was 1.667 (95%CI, 1.035-2.299).